OnCo
trialsTrialCompleted

AALL1521

aka COG AALL1521, INCB 18424-269

AALL1521 is the trial that added the JAK-blocking pill ruxolitinib to chemotherapy for children whose leukaemia looks like Philadelphia-positive disease but is driven by JAK signalling; it has finished treating patients and the survival results are awaited.